Strain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-Genome

PLoS Pathogens

Volumn 12, Issue 9, 2016, Pages

  van Opijnen, Tim ^a   Dedrick, Sandra ^a   Bento, José ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A2; ADENOSINE TRIPHOSPHATE PHOSPHORIBOSYLTRANSFERASE; ASPARTATE SEMIALDEHYDE DEHYDROGENASE; CARDIOLIPIN; DAPTOMYCIN; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; HEMOLYSIN; LIPOPROTEIN; MEMBRANE PROTEIN; POTASSIUM CHANNEL KCNQ2; PROTEIN TYROSINE KINASE A; ANTIINFECTIVE AGENT;

AMINO ACID METABOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CARBOHYDRATE METABOLISM; ENVIRONMENTAL STRESS; GENE EXPRESSION; GENE INTERACTION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; NONHUMAN; NUCLEOTIDE METABOLISM; POTASSIUM DEPLETION; POTASSIUM TRANSPORT; PROTEIN METABOLISM; STREPTOCOCCUS PNEUMONIAE; TRANSCRIPTION INITIATION; BACTERIAL GENOME; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; GROWTH, DEVELOPMENT AND AGING; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; GENE REGULATORY NETWORKS; GENOME, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 84989894424     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005869     Document Type: Article

References (104)

1. Nagai K, Davies TA, Jacobs MR, Appelbaum PC, Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrobial agents and chemotherapy. 2002;46(5):1273–80. 11959556; PubMed Central PMCID: PMCPMC127189.
2. Filipe SR, Tomasz A, Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(9):4891–6. doi: 10.1073/pnas.08006769710759563; PubMed Central PMCID: PMCPMC18328.
3. Hakenbeck R, Grebe T, Zahner D, Stock JB, beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Molecular microbiology. 1999;33(4):673–8. 10447877.
4. Haenni M, Moreillon P, Mutations in penicillin-binding protein (PBP) genes and in non-PBP genes during selection of penicillin-resistant Streptococcus gordonii. Antimicrobial agents and chemotherapy. 2006;50(12):4053–61. doi: 10.1128/AAC.00676-0617000741; PubMed Central PMCID: PMCPMC1693971.
5. Tomasz A, The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annual Reviews in Microbiology. 1979;33:113–37. 1132745480391671723related:q7-sSwNSuA8J.
6. Vakulenko S, Mobashery S, Versatility of aminoglycosides and prospects for their future. Clinical microbiology reviews. 2003;16(3):430–50. 6490603065717625770related:qhMpfhlBE1oJ. 12857776
7. Floss H, Yu T-W, Rifamycin mode of action, resistance, and biosynthesis. Chemical reviews. 2005;105:621–32. 40861973722518780related:_FSNpL8rkQAJ. 15700959
8. Drlica K, Malik M, Kerns RJ, Zhao X, Quinolone-mediated bacterial death. Antimicrobial agents and chemotherapy. 2008;52(2):385–92. 12080800095493710822related:5mNoFq6fp6cJ. 17724149
9. Drlica K, Malik M, Kerns R, Quinolone-mediated bacterial death. … agents and chemotherapy. 2008. 12080800095493710822related:5mNoFq6fp6cJ.
10. Floss H, Yu T-W, Rifamycin mode of action, resistance, and biosynthesis. Chemical reviews. 2005. 40861973722518780related:_FSNpL8rkQAJ.
11. Tomasz A, The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annual Reviews in Microbiology. 1979. 1132745480391671723related:q7-sSwNSuA8J.
12. Vakulenko S, Mobashery S, Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003. 6490603065717625770related:qhMpfhlBE1oJ.
13. Albert TJ, Dailidiene D, Dailide G, Norton JE, Kalia A, Richmond TA, et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nature Methods. 2005;2(12):951–3. 16299480
14. El'Garch F, Jeannot K, Hocquet D, Llanes-Barakat C, Plésiat P, Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrobial agents and chemotherapy. 2007;51(3):1016–21. 17194835
15. Kohanski MA, Collins JJ, Rewiring bacteria, two components at a time. Cell. 2008;133(6):947–8. doi: 10.1016/j.cell.2008.05.03518555769.
16. Kohanski MA, Dwyer DJ, Collins JJ, How antibiotics kill bacteria: from targets to networks. Nat Rev Micro. 2010;8(6):423–35. doi: 10.1038/nrmicro233320440275.
17. Baquero F, Coque TM, De La Cruz F, Ecology and Evolution as Targets: the Need for Novel Eco-Evo Drugs and Strategies To Fight Antibiotic Resistance. Antimicrobial agents and chemotherapy. 2011;55(8):3649–60. doi: 10.1128/AAC.00013-1121576439
18. Everett MJ, Jin YF, Ricci V, Piddock LJ, Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrobial agents and chemotherapy. 1996;40(10):2380–6. 8891148; PubMed Central PMCID: PMCPMC163538.
19. Piddock LJ, Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs. 1999;58Suppl 2:11–8. 10553699.
20. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D, Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrobial agents and chemotherapy. 2005;49(6):2343–51. doi: 10.1128/AAC.49.6.2343-2351.200515917531; PubMed Central PMCID: PMCPMC1140522.
21. Morgan-Linnell SK, Zechiedrich L, Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrobial agents and chemotherapy. 2007;51(11):4205–8. doi: 10.1128/AAC.00647-0717682104; PubMed Central PMCID: PMCPMC2151436.
22. Hooper DC, Mechanisms of fluoroquinolone resistance. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 1999;2(1):38–55. doi: 10.1054/drup.1998.006811504468.
23. Hooper DC, Mechanisms of action and resistance of older and newer fluoroquinolones. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;31Suppl 2:S24–8. doi: 10.1086/31405610984324.
24. Marcusson L, Frimodt-Møller N, Hughes D, Levin B, Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness. PLoS pathogens. 2009;5(8):e1000541. doi: 10.1371/journal.ppat.1000541.t00319662169
25. Rozen DE, McGee L, Levin BR, Klugman KP, Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial agents and chemotherapy. 2007;51(2):412–6. doi: 10.1128/AAC.01161-0617116668; PubMed Central PMCID: PMCPMC1797730.
26. Han J, Wang Y, Sahin O, Shen Z, Guo B, Shen J, et al. A fluoroquinolone resistance associated mutation in gyrA Affects DNA supercoiling in Campylobacter jejuni. Front Cell Infect Microbiol. 2012;2:21. doi: 10.3389/fcimb.2012.0002122919613; PubMed Central PMCID: PMCPMC3417464.
27. Baker S, Duy PT, Nga TV, Dung TT, Phat VV, Chau TT, et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. eLife. 2013;2:e01229. doi: 10.7554/eLife.0122924327559; PubMed Central PMCID: PMCPMC3857714.
28. Tuomanen L, Mitchel TJ, Morrison DA, Spratt B.G, The Pneumococcus. Washington: ASM Press; 2004.
29. WHOPneumococcal conjugate vaccine for childhood immunization—WHO position paper. Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2007;82(12):93–104.
30. CDCAntibiotic Resistance Threats in the Unites States. Centers for Disease Control and Prevention Threat Report. 2013;1:1–114.
31. Carter R, Wolf J, van Opijnen T, Muller M, Obert C, Burnham C, et al. Genomic Analyses of Pneumococci from Children with Sickle Cell Disease Expose Host-Specific Bacterial Adaptations and Deficits in Current Interventions. Cell Host and Microbe. 2014;15(5):587–99. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22252. doi: 10.1016/j.chom.2014.04.00524832453
32. Levy SB, Marshall B, Antibacterial resistance worldwide: causes, challenges and responses. Nature medicine. 2004;10(12):S122–9. 15577930
33. Walsh C, Where will new antibiotics come from?Nature reviews Microbiology. 2003;1(1):65–70. 15040181
34. Morar M, Wright GD, The genomic enzymology of antibiotic resistance. Annual Review of Genetics. 2010;44:25–51. doi: 10.1146/annurev-genet-102209-16351720822442
35. Hansman D, Bullen MM, A resistant pneumococcus. Lancet. 1963;ii:264–5.
36. Lynch J, Zhanel G, Streptococcus pneumoniae: Does Antimicrobial Resistance Matter?Seminars in Respiratory and Critical Care Medicine. 2009;30(02):210–38.
37. Samore MH, Magill MK, Alder SC, Severina E, Morrison-De Boer L, Lyon JL, et al. High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. Pediatrics. 2001;108(4):856–65. 11581436
38. Medini D, Donati C, Tettelin H, Masignani V, Rappuoli R, The microbial pan-genome. Current opinion in genetics & development. 2005;15(6):589–94. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22253.
39. Medini D, Serruto D, Parkhill J, Relman DA, Donati C, Moxon R, et al. Microbiology in the post-genomic era. Nature reviews Microbiology. 2008:1–12. doi: 10.1038/nrmicro1901
40. Henriques-Normark B, Blomberg C, Dagerhamn J, Bättig P, Normark S, The rise and fall of bacterial clones: Streptococcus pneumoniae. Nature reviews Microbiology. 2008;6(11):827–37. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22215. doi: 10.1038/nrmicro201118923410
41. Tenaillon O, Skurnik D, Picard B, Denamur E, The population genetics of commensal Escherichia coli. Nature Reviews Microbiology. 2010;8(3):207–17. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22214. doi: 10.1038/nrmicro229820157339
42. Donati C, Hiller NL, Tettelin H, Muzzi A, Croucher NJ, Angiuoli SV, et al. Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome biology. 2010;11(10):R107. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22209. doi: 10.1186/gb-2010-11-10-r10721034474
43. Hiller N, Janto B, Hogg J, Boissy R, Yu S, Powell E, et al. Comparative Genomic Analyses of Seventeen Streptococcus pneumoniae Strains: Insights into the Pneumococcal Supragenome. Journal of bacteriology. 2007;189(22):8186–95. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22210. 17675389
44. Dixon S, Costanzo M, Baryshnikova A, Andrews B, Andrews B, Boone C, Systematic Mapping of Genetic Interaction Networks. Annu. Rev. Genet. 2009; 43:601–625. doi: 10.1146/annurev.genet.39.073003.11475119712041
45. Boone C, Bussey H, Andrews B, Exploring genetic interactions and networks with yeast. Nat Rev Genet. 2007;8(6):437–49. doi: 10.1038/nrg208517510664
46. van Opijnen T, Bodi KL, Camilli A, Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nature Methods. 2009;6(10):767–72. doi: 10.1038/nmeth.137719767758
47. Mann B, van Opijnen T, Wang J, Obert C, Wang Y-D, Carter R, et al. Control of Virulence by Small RNAs in Streptococcus pneumoniae. PLoS pathogens. 2012;8(7):e1002788. doi: 10.1371/journal.ppat.100278822807675
48. van Opijnen T, Camilli A, A fine scale phenotype-genotype virulence map of a bacterial pathogen. Genome Res. 2012;22(12):2541–51. doi: 10.1101/gr.137430.11222826510
49. van Opijnen T, Camilli A, Transposon insertion sequencing: a new tool for systems-level analysis of microorganisms. Nature Reviews Microbiology. 2013;11:435–42. doi: 10.1038/nrmicro303323712350
50. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M, Chaba R, et al. Phenotypic landscape of a bacterial cell. Cell. 2011;144(1):143–56. doi: 10.1016/j.cell.2010.11.05221185072.
51. Fajardo A, Martinez-Martin N, Mercadillo M, Galan JC, Ghysels B, Matthijs S, et al. The neglected intrinsic resistome of bacterial pathogens. PloS one. 2008;3(2):e1619. doi: 10.1371/journal.pone.000161918286176
52. Tamae C, Liu A, Kim K, Sitz D, Hong J, Becket E, et al. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. Journal of bacteriology. 2008;190(17):5981–8. doi: 10.1128/JB.01982-0718621901; PubMed Central PMCID: PMC2519525.
53. Breidenstein EB, Khaira BK, Wiegand I, Overhage J, Hancock RE, Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrobial agents and chemotherapy. 2008;52(12):4486–91. doi: 10.1128/AAC.00222-0818824609
54. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, Khaira BK, et al. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. 2008;52(12):4213–9. doi: 10.1128/AAC.00507-0818824604
55. Girgis H, Hottes A, Tavazoie S, Genetic Architecture of Intrinsic Antibiotic Susceptibility. PloS one. 2009;4(5):e5629. doi: 10.1371/journal.pone.000562919462005
56. Pogliano J, Pogliano N, Silverman JA, Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. Journal of bacteriology. 2012;194(17):4494–504. doi: 10.1128/JB.00011-1222661688; PubMed Central PMCID: PMCPMC3415520.
57. Silverman JA, Perlmutter NG, Shapiro HM, Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2003;47(8):2538–44. 12878516; PubMed Central PMCID: PMCPMC166110.
58. Jung D, Rozek A, Okon M, Hancock RE, Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004;11(7):949–57. doi: 10.1016/j.chembiol.2004.04.02015271353.
59. Hachmann AB, Angert ER, Helmann JD, Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin. Antimicrobial agents and chemotherapy. 2009;53(4):1598–609. doi: 10.1128/AAC.01329-0819164152; PubMed Central PMCID: PMCPMC2663116.
60. Baltz RH, Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Current opinion in chemical biology. 2009;13(2):144–51. doi: 10.1016/j.cbpa.2009.02.03119303806
61. Hobbs JK, Miller K, O'Neill AJ, Chopra I, Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. The Journal of antimicrobial chemotherapy. 2008;62(5):1003–8. doi: 10.1093/jac/dkn32118669516.
62. Aaberge IS, Eng J, Lermark G, Løvik M, Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum. Microbial pathogenesis. 1995;18(2):141–52. 7643743
63. Tettelin H, Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniae. Science. 2001;293(5529):498–506.
64. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. Journal of clinical microbiology. 2001;39(7):2565–71. 11427569
65. Shi ZY, Enright MC, Wilkinson P, Griffiths D, Spratt BG, Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequence typing. Journal of clinical microbiology. 1998;36(12):3514–9. 9817864; PubMed Central PMCID: PMCPMC105231.
66. Shannon P, Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research. 2003;13(11):2498–504. doi: 10.1101/gr.123930314597658
67. Hyyrylainen HL, Marciniak BC, Dahncke K, Pietiainen M, Courtin P, Vitikainen M, et al. Penicillin-binding protein folding is dependent on the PrsA peptidyl-prolyl cis-trans isomerase in Bacillus subtilis. Molecular microbiology. 2010;77(1):108–27. doi: 10.1111/j.1365-2958.2010.07188.x20487272.
68. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ, Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrobial agents and chemotherapy. 2008;52(3):980–90. doi: 10.1128/AAC.01121-0718086846; PubMed Central PMCID: PMCPMC2258546.
69. Cui L, Tominaga E, Neoh HM, Hiramatsu K, Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2006;50(3):1079–82. doi: 10.1128/AAC.50.3.1079-1082.200616495273; PubMed Central PMCID: PMCPMC1426436.
70. Bayer AS, Schneider T, Sahl HG, Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139–58. doi: 10.1111/j.1749-6632.2012.06819.x23215859; PubMed Central PMCID: PMCPMC3556211.
71. Langklotz S, Baumann U, Narberhaus F, Structure and function of the bacterial AAA protease FtsH. Biochim Biophys Acta. 2012;1823(1):40–8. doi: 10.1016/j.bbamcr.2011.08.01521925212.
72. Kirstein J, Moliere N, Dougan D, Turgay K, Adapting the machine: adaptor proteins for Hsp100/Clp and AAA+ proteases. Nature Reviews Microbiology. 2009;7(8):589–99. doi: 10.1038/nrmicro218519609260
73. Hachmann AB, Sevim E, Gaballa A, Popham DL, Antelmann H, Helmann JD, Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrobial agents and chemotherapy. 2011;55(9):4326–37. doi: 10.1128/AAC.01819-1021709092; PubMed Central PMCID: PMCPMC3165287.
74. Friedman L, Alder JD, Silverman JA, Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2006;50(6):2137–45. doi: 10.1128/AAC.00039-0616723576; PubMed Central PMCID: PMCPMC1479123.
75. Rubio A, Conrad M, Haselbeck RJ, G CK, Brown-Driver V, Finn J, et al. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2011;55(1):364–7. doi: 10.1128/AAC.00429-1020974866; PubMed Central PMCID: PMCPMC3019644.
76. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, et al. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrobial agents and chemotherapy. 2009;53(6):2636–7. doi: 10.1128/AAC.01415-0819289517; PubMed Central PMCID: PMCPMC2687189.
77. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS, Genetic basis for daptomycin resistance in enterococci. Antimicrobial agents and chemotherapy. 2011;55(7):3345–56. doi: 10.1128/AAC.00207-1121502617
78. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, et al. Genetic basis for in vivo daptomycin resistance in enterococci. The New England journal of medicine. 2011;365(10):892–900. doi: 10.1056/NEJMoa101113821899450
79. Epstein W, The roles and regulation of potassium in bacteria. Prog Nucleic Acid Res Mol Biol. 2003;75:293–320. 14604015.
80. Novakova L, Bezouskova S, Pompach P, Spidlova P, Saskova L, Weiser J, et al. Identification of multiple substrates of the StkP Ser/Thr protein kinase in Streptococcus pneumoniae. Journal of bacteriology. 2010;192(14):3629–38. doi: 10.1128/JB.01564-0920453092; PubMed Central PMCID: PMCPMC2897338.
81. Real R, Vargas JM, The Probabilistic Basis of Jaccard's Index of Similarity. Society of Systematic Biologists. 1996;45(3):380–5.
82. Real R, Tables of significant values of Jaccard's index of similarity. Miscelània Zoològica. 1999;22(1):29–40.
83. Fuxman Bass JI, Diallo A, Nelson J, Soto JM, Myers CL, Walhout AJ, Using networks to measure similarity between genes: association index selection. Nat Methods. 2013;10(12):1169–76. doi: 10.1038/nmeth.272824296474; PubMed Central PMCID: PMCPMC3959882.
84. McLaggan D, Naprstek J, Buurman ET, Epstein W, Interdependence of K+ and glutamate accumulation during osmotic adaptation of Escherichia coli. The Journal of biological chemistry. 1994;269(3):1911–7. 7904996.
85. Frees D, Savijoki K, Varmanen P, Ingmer H, Clp ATPases and ClpP proteolytic complexes regulate vital biological processes in low GC, Gram-positive bacteria. Molecular microbiology. 2007;63(5):1285–95. doi: 10.1111/j.1365-2958.2007.05598.x17302811.
86. Zhang Q, Huang Y, Wang H, Xu W, Liu L, Yin Y, et al. The role of ClpP in protein expression of Streptococcus pneumoniae. Curr Microbiol. 2012;64(3):294–9. doi: 10.1007/s00284-011-0060-922198546.
87. Gerth U, Kock H, Kusters I, Michalik S, Switzer RL, Hecker M, Clp-dependent proteolysis down-regulates central metabolic pathways in glucose-starved Bacillus subtilis. Journal of bacteriology. 2008;190(1):321–31. doi: 10.1128/JB.01233-0717981983; PubMed Central PMCID: PMCPMC2223743.
88. Berg KH, Biornstad TJ, Johnsborg O, Havarstein LS, Properties and biological role of streptococcal fratricins. Appl Environ Microbiol. 2012;78(10):3515–22. doi: 10.1128/AEM.00098-1222407687; PubMed Central PMCID: PMCPMC3346361.
89. Eldholm V, Johnsborg O, Straume D, Ohnstad HS, Berg KH, Hermoso JA, et al. Pneumococcal CbpD is a murein hydrolase that requires a dual cell envelope binding specificity to kill target cells during fratricide. Molecular microbiology. 2010;76(4):905–17. doi: 10.1111/j.1365-2958.2010.07143.x20384696.
90. Havarstein LS, Martin B, Johnsborg O, Granadel C, Claverys JP, New insights into the pneumococcal fratricide: relationship to clumping and identification of a novel immunity factor. Molecular microbiology. 2006;59(4):1297–307. doi: 10.1111/j.1365-2958.2005.05021.x16430701.
91. Sham LT, Tsui HC, Land AD, Barendt SM, Winkler ME, Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets. Curr Opin Microbiol. 2012;15(2):194–203. doi: 10.1016/j.mib.2011.12.01322280885; PubMed Central PMCID: PMCPMC3322672.
92. Barendt SM, Sham LT, Winkler ME, Characterization of mutants deficient in the L,D-carboxypeptidase (DacB) and WalRK (VicRK) regulon, involved in peptidoglycan maturation of Streptococcus pneumoniae serotype 2 strain D39. Journal of bacteriology. 2011;193(9):2290–300. doi: 10.1128/JB.01555-1021378199; PubMed Central PMCID: PMCPMC3133071.
93. Pagliero E, Dublet B, Frehel C, Dideberg O, Vernet T, Di Guilmi A, The Inactivation of a New Peptidoglycan Hydrolase Pmp23 Leads to Abnormal Septum Formation in Streptococcus pneumoniae. Open Microbiol J. 2008;2:107–14. doi: 10.2174/187428580080201010719088920; PubMed Central PMCID: PMCPMC2593039.
94. Camargo IL, Neoh HM, Cui L, Hiramatsu K, Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrobial agents and chemotherapy. 2008;52(12):4289–99. doi: 10.1128/AAC.00417-0818824611; PubMed Central PMCID: PMCPMC2592861.
95. Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 2012;56(1):92–102. doi: 10.1128/AAC.00432-1021986832; PubMed Central PMCID: PMCPMC3256076.
96. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML, Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clinical microbiology reviews. 2010;23(1):99–139. doi: 10.1128/CMR.00042-0920065327; PubMed Central PMCID: PMCPMC2806658.
97. Fischer A, Yang SJ, Bayer AS, Vaezzadeh AR, Herzig S, Stenz L, et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. The Journal of antimicrobial chemotherapy. 2011;66(8):1696–711. doi: 10.1093/jac/dkr19521622973; PubMed Central PMCID: PMCPMC3133485.
98. Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K, Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Molecular microbiology. 2003;49(3):807–21. 12864861.
99. Gillespie JJ, Wattam AR, Cammer SA, Gabbard JL, Shukla MP, Dalay O, et al. PATRIC: the comprehensive bacterial bioinformatics resource with a focus on human pathogenic species. Infection and immunity. 2011;79(11):4286–98. doi: 10.1128/IAI.00207-1121896772
100. Iyer R, Baliga NS, Camilli A, Catabolite control protein A (CcpA) contributes to virulence and regulation of sugar metabolism in Streptococcus pneumoniae. Journal of bacteriology. 2005;187(24):8340–9. doi: 10.1128/JB.187.24.8340-8349.200516321938.
101. van Opijnen T, Lazinski DW, Camilli A, Genome-Wide Fitness and Genetic Interactions Determined by Tn-seq, a High-Throughput Massively Parallel Sequencing Method for Microorganisms. Current protocols in molecular biology. 2014;106:7.16.1–7.24. papers://58864D70-D09B-4A16-B641-1A3EEB7FE0BA/Paper/p22298.
102. van Opijnen T, Lazinski DW, Camilli A, Genome-Wide Fitness and Genetic Interactions Determined by Tn-seq, a High-Throughput Massively Parallel Sequencing Method for Microorganisms. Curr Protoc Microbiol. 2015;36:1E 3 1–E 3 24. doi: 10.1002/9780471729259.mc01e03s3625641100.
103. van Opijnen T, Boerlijst MC, Berkhout B, Effects of Random Mutations in the Human Immunodeficiency Virus Type 1 Transcriptional Promoter on Viral Fitness in Different Host Cell Environments. Journal of Virology. 2006;80:6678–85. 3722609299033220181. 16775355
104. Orlov DS, Nguyen T, Lehrer RI, Potassium release, a useful tool for studying antimicrobial peptides. J Microbiol Methods. 2002;49(3):325–8. 11869799.